HRP20231196T1 - Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba - Google Patents
Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba Download PDFInfo
- Publication number
- HRP20231196T1 HRP20231196T1 HRP20231196TT HRP20231196T HRP20231196T1 HR P20231196 T1 HRP20231196 T1 HR P20231196T1 HR P20231196T T HRP20231196T T HR P20231196TT HR P20231196 T HRP20231196 T HR P20231196T HR P20231196 T1 HRP20231196 T1 HR P20231196T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- antibody
- seq
- binding fragment
- sequence
- Prior art date
Links
- 241000907316 Zika virus Species 0.000 title claims 2
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 208000020329 Zika virus infectious disease Diseases 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 208000001455 Zika Virus Infection Diseases 0.000 claims 3
- 208000035332 Zika virus disease Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (13)
1. Izolirano protutijelo ili njegov fragment koji se veže na antigen, koje se specifično veže na epitop Zika virusa i neutralizira infekciju Zika virusom, pri čemu protutijelo ili njegov fragment koji se veže na antigen sadrži aminokiselinske sekvence CDRH1, CDRH2, i CDRH3 i aminokiselinske sekvence CDRL1, CDRL2, i CDRL3 (i) prema SEQ ID NOs: 1 - 5 i 7; (ii) prema SEQ ID NOs: 1 - 4 i 6 - 7; (iii) prema SEQ ID NOs: 19 - 23 i 25; (iv) prema SEQ ID NOs: 19-22 i 24 - 25; (v) prema SEQ ID NOs: 37 - 41 i 43; (vi) prema SEQ ID NOs: 37 - 40 i 42 - 43; (vii) prema SEQ ID NOs: 73 - 77 i 79; ili (viii) prema SEQ ID NOs: 73 - 76 i 78 - 79.
2. Protutijelo, ili njegov fragment koji se veže na antigen, prema zahtjevu 1, naznačeno time što protutijelo, ili njegov fragment koji se veže na antigen, sadrži Fc ostatak; poželjno protutijelo, ili njegov fragment koji se veže na antigen, sadrži mutaciju u Fc ostatku, pri čemu navedena mutacija smanjuje vezanje protutijela na Fc receptor; poželjnije protutijelo, ili njegov fragment koji se veže na antigen, sadrži mutaciju CH2 L4A, mutaciju CH2 L5A, ili obje.
3. Protutijelo, ili njegov fragment koji se veže na antigen, prema zahtjevu 1 ili 2, naznačeno time što protutijelo, ili njegov fragment koji se veže na antigen, sadrži (i) aminokiselinsku sekvencu varijabilne regije teškog lanca (VH) prema SEQ ID NO: 8 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence i/ili aminokiselinsku sekvencu varijabilne regije lakog lanca (VL) prema SEQ ID NO: 9 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence; (ii) aminokiselinsku sekvencu varijabilne regije teškog lanca (VH) prema SEQ ID NO: 26 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence i/ili aminokiselinsku sekvencu varijabilne regije lakog lanca (VL) prema SEQ ID NO: 27 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence; (iii) aminokiselinsku sekvencu varijabilne regije teškog lanca (VH) prema SEQ ID NO: 44 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence i/ili aminokiselinsku sekvencu varijabilne regije lakog lanca (VL) prema SEQ ID NO: 45 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence; ili (iv) aminokiselinsku sekvencu varijabilne regije teškog lanca (VH) prema SEQ ID NO: 80 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence i/ili aminokiselinsku sekvencu varijabilne regije lakog lanca (VL) prema SEQ ID NO: 81 ili funkcionalnu varijantu njegove sekvence koja ima najmanje 70%, najmanje 75%, najmanje 80%, najmanje 85%, najmanje 88%, najmanje 90%, najmanje 92%, najmanje 95%, najmanje 96%, najmanje 97%, najmanje 98% ili najmanje 99% identičnosti sekvence.
4. Protutijelo, ili njegov fragment koji se veže na antigen, prema bilo kojem od prethodnih zahtjeva naznačeno time što se koristi kao lijek.
5. Molekula nukleinske kiseline naznačena time što sadrži polinukleotid koji kodira protutijelo, ili njegov fragment koji veže antigen, prema bilo kojem od prethodnih zahtjeva.
6. Vektor naznačen time što sadrži molekulu nukleinske kiseline prema zahtjevu 5.
7. Stanica koja eksprimira protutijelo, ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3; ili koja sadrži vektor prema zahtjevu 6.
8. Farmaceutski pripravak koji sadrži protutijelo, ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3, nukleinsku kiselinu prema zahtjevu 5, vektor prema zahtjevu 6 i/ili stanicu prema zahtjevu 7; i, izborno, farmaceutski prihvatljivu pomoćnu tvar, sredstvo za razrjeđivanje ili nosač.
9. Protutijelo, ili njegov fragment koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3, nukleinska kiselina prema zahtjevu 5, vektor prema zahtjevu 6, stanica prema zahtjevu 7, ili farmaceutski pripravak prema zahtjevu 8 za upotrebu u prevenciji ili liječenju infekcije Zika virusom.
10. Protutijelo, ili njegov fragment koji se veže na antigen, nukleinska kiselina, vektor, stanica ili farmaceutski pripravak za upotrebu prema zahtjevu 9, naznačeno time što se protutijelo ili njegov fragment koji se veže na antigen, nukleinska kiselina, vektor, stanica, ili farmaceutski pripravak primjenjuje u kombinaciji s inhibitorom kontrolne točke.
11. Upotreba protutijela, ili njegovog fragmenta koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3 u in vitro dijagnostici infekcije Zika virusom.
12. Upotreba protutijela ili njegovog fragmenta koji se veže na antigen, prema bilo kojem od zahtjeva 1 do 3 za in vitro praćenje kvalitete anti-Zika cjepiva provjerom sadrži li antigen navedenog cjepiva specifični epitop u ispravnoj konformaciji.
13. Komplet dijelova koji sadrži najmanje jedno protutijelo, ili njegov fragment koji veže antigen, prema bilo kojem od zahtjeva 1 do 3, najmanje jednu nukleinsku kiselinu prema zahtjevu 5, najmanje jedan vektor prema zahtjevu 6, najmanje jednu stanicu prema zahtjevu 7, ili najmanje jedan farmaceutski pripravak prema zahtjevu 8, i sredstva za primjenu protutijela ili njegovog fragmenta koji veže antigen, nukleinske kiseline, vektora, stanice ili farmaceutskog pripravka.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2016/066684 WO2018010789A1 (en) | 2016-07-13 | 2016-07-13 | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
EP17742985.9A EP3484915B1 (en) | 2016-07-13 | 2017-07-12 | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
PCT/EP2017/067581 WO2018011283A1 (en) | 2016-07-13 | 2017-07-12 | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231196T1 true HRP20231196T1 (hr) | 2024-01-19 |
Family
ID=56413654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231196TT HRP20231196T1 (hr) | 2016-07-13 | 2017-07-12 | Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba |
Country Status (31)
Country | Link |
---|---|
US (3) | US11117954B2 (hr) |
EP (2) | EP4342911A1 (hr) |
JP (2) | JP7252888B2 (hr) |
KR (1) | KR102595764B1 (hr) |
CN (2) | CN116199775A (hr) |
AU (1) | AU2017297757B2 (hr) |
BR (1) | BR112018074456A2 (hr) |
CA (1) | CA3024374A1 (hr) |
CL (2) | CL2019000067A1 (hr) |
CO (1) | CO2019001111A2 (hr) |
CR (1) | CR20190066A (hr) |
DK (1) | DK3484915T5 (hr) |
DO (2) | DOP2019000006A (hr) |
EA (1) | EA201990243A1 (hr) |
EC (1) | ECSP19009170A (hr) |
ES (1) | ES2959883T3 (hr) |
FI (1) | FI3484915T3 (hr) |
HR (1) | HRP20231196T1 (hr) |
HU (1) | HUE063272T2 (hr) |
IL (1) | IL262710B2 (hr) |
LT (1) | LT3484915T (hr) |
MX (1) | MX2019000526A (hr) |
MY (1) | MY190553A (hr) |
PE (1) | PE20190398A1 (hr) |
PH (1) | PH12018502348A1 (hr) |
PL (1) | PL3484915T3 (hr) |
SG (1) | SG11201809879WA (hr) |
SI (1) | SI3484915T1 (hr) |
UA (1) | UA126381C2 (hr) |
WO (2) | WO2018010789A1 (hr) |
ZA (1) | ZA201807467B (hr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11946017B2 (en) | 2016-07-13 | 2024-04-02 | Evonik Operations Gmbh | Method of separating lipids from a lysed lipids containing biomass |
MY191894A (en) | 2016-10-13 | 2022-07-18 | Nat Univ Singapore | Antibodies that bind zika virus envelope protein and uses thereof |
WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
EP3527664A1 (en) | 2018-02-15 | 2019-08-21 | Evonik Degussa GmbH | Method of isolating lipids from a lipids containing biomass |
JP2019152666A (ja) * | 2018-03-02 | 2019-09-12 | 富士レビオ株式会社 | ジカウイルスを検出する方法及びキット |
CA3098373A1 (en) | 2018-04-24 | 2019-10-31 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination |
RU2760575C1 (ru) | 2018-05-15 | 2021-11-29 | Эвоник Оперейшнс Гмбх | Способ выделения липидов из содержащей липиды биомассы с помощью гидрофобного диоксида кремния |
US11976253B2 (en) | 2018-05-15 | 2024-05-07 | Evonik Operations Gmbh | Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion |
WO2020061159A1 (en) * | 2018-09-20 | 2020-03-26 | Vanderbilt University | Human antibodies to zika virus |
WO2020078568A1 (en) | 2018-10-19 | 2020-04-23 | Humabs Biomed Sa | Antibodies and methods for treatment of lyssavirus infection |
WO2020092564A1 (en) * | 2018-10-31 | 2020-05-07 | Icahn School Of Medicine At Mount Sinai | Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof |
JP7463366B2 (ja) * | 2018-11-20 | 2024-04-08 | タケダ ワクチン,インコーポレイテッド | 新規の抗ジカウイルス抗体及びその使用 |
WO2020245663A1 (en) * | 2019-06-01 | 2020-12-10 | Institut Pasteur | Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection |
US20230085393A1 (en) * | 2019-11-19 | 2023-03-16 | Vanderbilt University | Human antibodies that neutralize zika virus and methods of use therefor |
CN111100201B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
CN111138534B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
JP7471555B2 (ja) * | 2020-02-20 | 2024-04-22 | 国立感染症研究所長 | フラビウイルス交差中和抗体及び医薬組成物 |
JP2023526493A (ja) | 2020-05-20 | 2023-06-21 | タケダ ワクチン,インコーポレイテッド | ジカウイルス特異的抗体の検出方法 |
WO2021236225A1 (en) | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
US20230204567A1 (en) | 2020-05-20 | 2023-06-29 | Takeda Vaccines, Inc. | Method for determining the potency of antigens |
WO2022001803A1 (zh) * | 2020-06-28 | 2022-01-06 | 神州细胞工程有限公司 | 一种降低病毒ade效应的方法 |
EP4313102A2 (en) * | 2021-04-01 | 2024-02-07 | A2 Biotherapeutics, Inc. | Polypeptides targeting hla-a*11 and methods of use thereof |
CN112921124B (zh) * | 2021-04-08 | 2021-09-28 | 广东创晟控股集团有限公司 | 一种快速检测病毒的试剂盒 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
US7785799B2 (en) | 2002-08-16 | 2010-08-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain III antigens |
AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
WO2005000898A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
CN101802197A (zh) | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC(ScFc)区、包含其的结合多肽及与其相关的方法 |
DK2350128T3 (da) | 2008-10-22 | 2014-12-01 | Inst Research In Biomedicine | Fremgangsmåder til fremstilling af antistoffer fra plasmaceller |
CA2901358C (en) * | 2013-03-15 | 2022-07-26 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
JP2019511221A (ja) | 2016-03-11 | 2019-04-25 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 弱毒化された生ジカウイルスワクチン |
WO2017181098A2 (en) * | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
PT3658557T (pt) | 2017-07-28 | 2024-09-11 | Nimbus Lakshmi Inc | Inibidores de tyk2 e usos dos mesmos |
-
2016
- 2016-07-13 WO PCT/EP2016/066684 patent/WO2018010789A1/en active Application Filing
-
2017
- 2017-07-12 KR KR1020197004192A patent/KR102595764B1/ko active IP Right Grant
- 2017-07-12 CR CR20190066A patent/CR20190066A/es unknown
- 2017-07-12 CN CN202211721078.3A patent/CN116199775A/zh active Pending
- 2017-07-12 LT LTEPPCT/EP2017/067581T patent/LT3484915T/lt unknown
- 2017-07-12 DK DK17742985.9T patent/DK3484915T5/da active
- 2017-07-12 ES ES17742985T patent/ES2959883T3/es active Active
- 2017-07-12 CA CA3024374A patent/CA3024374A1/en active Pending
- 2017-07-12 IL IL262710A patent/IL262710B2/en unknown
- 2017-07-12 HU HUE17742985A patent/HUE063272T2/hu unknown
- 2017-07-12 SG SG11201809879WA patent/SG11201809879WA/en unknown
- 2017-07-12 BR BR112018074456-5A patent/BR112018074456A2/pt unknown
- 2017-07-12 CN CN201780042888.7A patent/CN109563157B/zh active Active
- 2017-07-12 MX MX2019000526A patent/MX2019000526A/es unknown
- 2017-07-12 EP EP23191207.2A patent/EP4342911A1/en not_active Withdrawn
- 2017-07-12 JP JP2019501482A patent/JP7252888B2/ja active Active
- 2017-07-12 HR HRP20231196TT patent/HRP20231196T1/hr unknown
- 2017-07-12 EA EA201990243A patent/EA201990243A1/ru unknown
- 2017-07-12 SI SI201731420T patent/SI3484915T1/sl unknown
- 2017-07-12 MY MYPI2018704108A patent/MY190553A/en unknown
- 2017-07-12 PL PL17742985.9T patent/PL3484915T3/pl unknown
- 2017-07-12 UA UAA201901101A patent/UA126381C2/uk unknown
- 2017-07-12 US US16/317,533 patent/US11117954B2/en active Active
- 2017-07-12 EP EP17742985.9A patent/EP3484915B1/en active Active
- 2017-07-12 FI FIEP17742985.9T patent/FI3484915T3/fi active
- 2017-07-12 PE PE2019000034A patent/PE20190398A1/es unknown
- 2017-07-12 AU AU2017297757A patent/AU2017297757B2/en active Active
- 2017-07-12 WO PCT/EP2017/067581 patent/WO2018011283A1/en unknown
-
2018
- 2018-11-07 ZA ZA2018/07467A patent/ZA201807467B/en unknown
- 2018-11-07 PH PH12018502348A patent/PH12018502348A1/en unknown
-
2019
- 2019-01-08 DO DO2019000006A patent/DOP2019000006A/es unknown
- 2019-01-09 CL CL2019000067A patent/CL2019000067A1/es unknown
- 2019-02-05 CO CONC2019/0001111A patent/CO2019001111A2/es unknown
- 2019-02-07 EC ECSENADI20199170A patent/ECSP19009170A/es unknown
-
2021
- 2021-02-10 DO DO2021000026A patent/DOP2021000026A/es unknown
- 2021-06-01 US US17/335,799 patent/US20210363227A1/en not_active Abandoned
- 2021-06-01 US US17/335,792 patent/US11912757B2/en active Active
- 2021-11-12 CL CL2021002994A patent/CL2021002994A1/es unknown
-
2023
- 2023-02-10 JP JP2023019144A patent/JP2023062036A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231196T1 (hr) | Nova protutijela koja se specifično vežu na epitope zika virusa i njihova upotreba | |
HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
JP2018535650A5 (hr) | ||
RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
JP2018521638A5 (hr) | ||
JP2020500538A5 (hr) | ||
JP2011528902A5 (hr) | ||
JP2012504955A5 (hr) | ||
US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
JP2011528901A5 (hr) | ||
CN110642944B (zh) | 一种中和人感染h7n9甲型流感病毒的抗体及其用途 | |
RU2016100892A (ru) | Антитела против tweakr и их применение | |
CN107667114B (zh) | 中和抗流感结合分子及其用途 | |
US11730813B2 (en) | Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof | |
US10654915B2 (en) | Antibodies useful in passive influenza immunization | |
RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
JP2010516229A5 (hr) | ||
RU2012112829A (ru) | Анти-gitr-антитела | |
JP2023071956A5 (hr) | ||
RU2014145536A (ru) | Антитело против adamts-5, его производные и их применение | |
RU2017128512A (ru) | Антитела к теофиллину и способы их применения | |
RU2018115246A (ru) | Композиции антител к вич и способы их применения | |
JP2012510802A (ja) | 完全ヒトインフルエンザm2特異的抗体 |